Developer docs
API playgroundTry for free, no card

Search company profiles

Vor Biopharma

Full company profile

uuid00000wd

Namestring
Vor Biopharma
Legal namestring
Vor Biopharma, Inc.
Websiteurl
vorbio.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Vor Biopharma is a clinical-stage biotechnology company headquartered in Boston, Massachusetts that develops therapies for autoimmune diseases. Originally founded in 2017 to develop CRISPR-based gene-edited stem cell therapies for hematological malignancies (CD33-deleted trem-cel for AML and MDS), the company underwent a major strategic pivot in June 2025, reducing its workforce by approximately 95% and refocusing entirely on autoimmune disease drug development following a licensing deal with RemeGen Co., Ltd. Vor Bio is publicly traded on NASDAQ under ticker VOR.

The company's core asset is telitacicept, a first-in-class TACI-Fc fusion protein that simultaneously inhibits BAFF and APRIL, two upstream B-cell survival signals that drive harmful B-cell maturation, proliferation, and autoantibody production. Under the June 2025 license worth up to $4 billion, Vor Bio holds exclusive ex-Greater China rights; RemeGen independently develops, manufactures, and commercializes the drug in China under the brand Teliain, where it has received approvals for SLE (2023), RA (2024), MG (2025), Sjögren's disease (June 2026), and IgA nephropathy (June 2026). Vor Bio is advancing two global Phase 3 trials: UPSTREAM MG (~180 patients) and UPSTREAM SjD (~250 patients), with topline MG data expected in H1 2027.

Vor Bio's business model is currently pre-commercial in the US, with no product revenue. The company generates no direct revenue from Chinese sales and is funded entirely through equity capital, having raised over $500 million in 2025-2026 to extend its cash runway into early 2029. Management is building US commercialization infrastructure under CEO Jean-Paul Kress (former MorphoSys CEO) with commercial leadership hired from Sarepta, argenx, and Vertex, targeting a future US specialty pharmacy launch contingent on FDA approval.

Short descriptiontext

Vor Biopharma is a clinical-stage biotechnology company that holds ex-Greater China rights to telitacicept, a first-in-class dual BAFF/APRIL inhibitor licensed from RemeGen, and is advancing global Phase 3 trials in generalized myasthenia gravis and primary Sjögren's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autoimmune disease therapeutics, BAFF APRIL inhibition, clinical stage biotechnology, TACI-Fc fusion protein, Phase 3 clinical trials
Industry3 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Telitacicept (ex-Greater China)
TypeLicensing Royalties
Description

Vor Bio holds exclusive rights to develop and commercialize telitacicept outside Greater China. RemeGen independently developed the drug and holds responsibility for development, regulatory approvals, and commercialization within China. Vor Bio is advancing global Phase 3 trials for myasthenia gravis and Sjögren's disease toward potential US FDA approval and commercial launch.

vorbio.com
2RemeGen licensing and warrant stake
TypeLicensing Royalties
Description

The June 2025 licensing deal with RemeGen included $45 million upfront plus warrants giving a RemeGen subsidiary a 23% stake in Vor Bio. This creates a financial alignment where Vor's success directly benefits RemeGen shareholders.

ad-hoc-news.de
3Tens of thousands of patients treated commercially in China
TypeLicensing Royalties
Description

Telitacicept (marketed as Teliain in China by RemeGen) is already commercially approved and generating revenue in China across SLE, RA, MG, Sjögren's disease, and IgA nephropathy, with tens of thousands of patients treated. Vor receives no direct commercial revenue from China sales but benefits from the large real-world safety and efficacy dataset.

vorbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vor Biopharma is a clinical-stage biotechnology company developing telitacicept, a first-in-class TACI-Fc fusion protein that simultaneously inhibits BAFF and APRIL signaling pathways to treat autoimmune diseases. The company holds ex-Greater China rights licensed from RemeGen and is advancing global Phase 3 trials in generalized myasthenia gravis (UPSTREAM MG) and primary Sjögren's disease (UPSTREAM SjD), while the drug is already commercially approved in China for SLE, RA, and MG.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 58.9-59% reduction in urinary protein-to-creatinine ratio (UPCR) in IgA nephropathy patients at Week 39 in Phase 3 TELIGAN trial
+4 more records
Product overview1 text field

Vor Biopharma is a clinical-stage biotechnology company focused on advancing telitacicept, a potential best- and first-in-class dual BAFF/APRIL inhibitor (TACI-Fc fusion protein) for autoimmune diseases. The company's portfolio centers on telitacicept, which has been approved in China for three autoimmune indications (SLE, RA, MG) with additional approvals pending. Global Phase 3 trials are underway for generalized myasthenia gravis (UPSTREAM MG) and Sjögren's disease (UPSTREAM SjD). Telitacicept works by blocking BAFF and APRIL signals that sustain harmful B cells, reducing autoantibody production and restoring immune balance.

Product and service1 record
1Telitacicept
CategoryBiologic drug product
Description

A first-in-class dual BAFF/APRIL inhibitor (TACI-Fc fusion protein) designed to rebalance immunity by silencing signals that drive harmful B-cell maturation, proliferation, and survival, thereby reducing autoantibody production in autoimmune diseases. Vor Bio holds ex-Greater China development and commercialization rights.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-26
Description

Vor Bio entered a licensing agreement with RemeGen worth up to $4 billion for ex-Greater China rights to telitacicept, a dual BAFF/APRIL inhibitor for autoimmune diseases. The deal included $45 million upfront plus warrants giving a RemeGen subsidiary a 23% stake in Vor. RemeGen independently develops, manufactures, and commercializes telitacicept in China, where it holds multiple approvals for autoimmune diseases including SLE, RA, MG, Sjögren's disease, and IgA nephropathy.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage autoimmune biotech with efgartigimod (VYVGART), an FcRn antagonist approved for generalized myasthenia gravis — the same lead indication as Vor's UPSTREAM MG Phase 3 program. Directly comparable business model (clinical-to-commercial autoimmune biotech) and target patient population.

TypeDirect peer
Description

Chinese biotech that developed telitacicept and is Vor Bio's licensing partner. Holds Chinese commercial rights and manufactures the drug; directly comparable asset (telitacicept itself) and overlapping autoimmune disease focus.

TypeBroad incumbent
Description

Specialty immunology biotech commercializing Monjuvi (tafasitamab) in lymphoma and pipeline assets in autoimmune disease — recently acquired by Novartis. Comparable as an autoimmune/hematology-focused biotech; Vor Bio's CEO Jean-Paul Kress was previously MorphoSys CEO.

TypeBroad incumbent
Description

Commercial-stage biotech with multiple rare disease product launches. Vor Bio's CCO Dallan Murray was previously EVP/CCO at Sarepta; comparable as a rare/specialty disease launch and commercialization platform.

5Bristol Myers Squibb
TypeBroad incumbent
Description

Major pharma with extensive autoimmune franchise including Zeposia (SjD/MS), deucravacitinib, and several lupus/RA assets. Competes with Vor Bio's telitacicept pipeline across multiple overlapping indications including SLE and SjD.

TypeBroad incumbent
Description

Major autoimmune franchise with Humira, Rinvoq, and Skyrizi across RA, lupus, and other indications. Vor Bio's CMAO Navid Khan previously led immunology translational science at AbbVie; broad competitive overlap in autoimmune disease.

TypeBroad incumbent
Description

Major pharma with autoimmune pipeline including anifrolumab (SLE) and several immunology assets. Competes across multiple of Vor Bio's target indications including lupus, RA, and rare autoimmune diseases.

TypeBroad incumbent
Description

Major pharma with autoimmune franchise including Dupixent and multiple B-cell targeting programs. Vor Bio CEO Jean-Paul Kress serves on Sanofi's board. Competes broadly in immunology and rare autoimmune disease.

TypeEmerging player
Description

Specialty immunology company with rozanolixizumab (Rystiggo) approved for generalized myasthenia gravis — directly competing with Vor's UPSTREAM MG program. Comparable focus on Fc receptor and B-cell pathway modulators in autoimmune neurology.

TypeOthers
Description

Major biotech with growing autoimmune/inflammation franchise. Vor Bio's CCO Dallan Murray previously led Vertex's INCIVEK launch — the fastest biotech launch to $1B at the time. Comparable as a high-growth specialty biotech with strong commercial execution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vor Biopharma

Biopharmaceuticalsvorbio.com

Vor Biopharma is a clinical-stage biotechnology company that holds ex-Greater China rights to telitacicept, a first-in-class dual BAFF/APRIL inhibitor licensed from RemeGen, and is advancing global Phase 3 trials in generalized myasthenia gravis and primary Sjögren's disease.

What Vor Biopharma does

Vor Biopharma is a clinical-stage biotechnology company headquartered in Boston, Massachusetts that develops therapies for autoimmune diseases. Originally founded in 2017 to develop CRISPR-based gene-edited stem cell therapies for hematological malignancies (CD33-deleted trem-cel for AML and MDS), the company underwent a major strategic pivot in June 2025, reducing its workforce by approximately 95% and refocusing entirely on autoimmune disease drug development following a licensing deal with RemeGen Co., Ltd. Vor Bio is publicly traded on NASDAQ under ticker VOR.

The company's core asset is telitacicept, a first-in-class TACI-Fc fusion protein that simultaneously inhibits BAFF and APRIL, two upstream B-cell survival signals that drive harmful B-cell maturation, proliferation, and autoantibody production. Under the June 2025 license worth up to $4 billion, Vor Bio holds exclusive ex-Greater China rights; RemeGen independently develops, manufactures, and commercializes the drug in China under the brand Teliain, where it has received approvals for SLE (2023), RA (2024), MG (2025), Sjögren's disease (June 2026), and IgA nephropathy (June 2026). Vor Bio is advancing two global Phase 3 trials: UPSTREAM MG (~180 patients) and UPSTREAM SjD (~250 patients), with topline MG data expected in H1 2027.

Vor Bio's business model is currently pre-commercial in the US, with no product revenue. The company generates no direct revenue from Chinese sales and is funded entirely through equity capital, having raised over $500 million in 2025-2026 to extend its cash runway into early 2029. Management is building US commercialization infrastructure under CEO Jean-Paul Kress (former MorphoSys CEO) with commercial leadership hired from Sarepta, argenx, and Vertex, targeting a future US specialty pharmacy launch contingent on FDA approval.

Vor Biopharma firmographics

Firmographics
Name
Vor Biopharma
Legal name
Vor Biopharma, Inc.
Website
https://vorbio.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Vor Biopharma is a clinical-stage biotechnology company that holds ex-Greater China rights to telitacicept, a first-in-class dual BAFF/APRIL inhibitor licensed from RemeGen, and is advancing global Phase 3 trials in generalized myasthenia gravis and primary Sjögren's disease.
Ownership category
akta.pro rank

Vor Biopharma industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Autoimmune disease therapeutics
  • BAFF APRIL inhibition
  • Clinical stage biotechnology
  • TACI-Fc fusion protein
  • Phase 3 clinical trials

Where Vor Biopharma is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vor Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Telitacicept (ex-Greater China): Vor Bio holds exclusive rights to develop and commercialize telitacicept outside Greater China. RemeGen independently developed the drug and holds responsibility for development, regulatory approvals, and commercialization within China. Vor Bio is advancing global Phase 3 trials for myasthenia gravis and Sjögren's disease toward potential US FDA approval and commercial launch.
  2. RemeGen licensing and warrant stake: The June 2025 licensing deal with RemeGen included $45 million upfront plus warrants giving a RemeGen subsidiary a 23% stake in Vor Bio. This creates a financial alignment where Vor's success directly benefits RemeGen shareholders.
  3. Tens of thousands of patients treated commercially in China: Telitacicept (marketed as Teliain in China by RemeGen) is already commercially approved and generating revenue in China across SLE, RA, MG, Sjögren's disease, and IgA nephropathy, with tens of thousands of patients treated. Vor receives no direct commercial revenue from China sales but benefits from the large real-world safety and efficacy dataset.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Vor Biopharma product offering

Product offering

Core offering

Vor Biopharma is a clinical-stage biotechnology company developing telitacicept, a first-in-class TACI-Fc fusion protein that simultaneously inhibits BAFF and APRIL signaling pathways to treat autoimmune diseases. The company holds ex-Greater China rights licensed from RemeGen and is advancing global Phase 3 trials in generalized myasthenia gravis (UPSTREAM MG) and primary Sjögren's disease (UPSTREAM SjD), while the drug is already commercially approved in China for SLE, RA, and MG.

Product overview

Vor Biopharma is a clinical-stage biotechnology company focused on advancing telitacicept, a potential best- and first-in-class dual BAFF/APRIL inhibitor (TACI-Fc fusion protein) for autoimmune diseases. The company's portfolio centers on telitacicept, which has been approved in China for three autoimmune indications (SLE, RA, MG) with additional approvals pending. Global Phase 3 trials are underway for generalized myasthenia gravis (UPSTREAM MG) and Sjögren's disease (UPSTREAM SjD). Telitacicept works by blocking BAFF and APRIL signals that sustain harmful B cells, reducing autoantibody production and restoring immune balance.

Differentiator

Problem solved

Functional benefit

Products and services

  • Telitacicept A first-in-class dual BAFF/APRIL inhibitor (TACI-Fc fusion protein) designed to rebalance immunity by silencing signals that drive harmful B-cell maturation, proliferation, and survival, thereby reducing autoantibody production in autoimmune diseases. Vor Bio holds ex-Greater China development and commercialization rights.

Quantifiable outcome

  • 58.9-59% reduction in urinary protein-to-creatinine ratio (UPCR) in IgA nephropathy patients at Week 39 in Phase 3 TELIGAN trial
  • +4 more outcomes

Companies that use Vor Biopharma

Customer profile

Segments1 record

Ideal customer profiles2 records

Vor Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vor Biopharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • RemeGen Co., Ltd.coreStrategic or Co-development Partner · 26 June 2025Vor Bio entered a licensing agreement with RemeGen worth up to $4 billion for ex-Greater China rights to telitacicept, a dual BAFF/APRIL inhibitor for autoimmune diseases. The deal included $45 million upfront plus warrants giving a RemeGen subsidiary a 23% stake in Vor. RemeGen independently develops, manufactures, and commercializes telitacicept in China, where it holds multiple approvals for autoimmune diseases including SLE, RA, MG, Sjögren's disease, and IgA nephropathy.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Vor Biopharma competitors and assessment

Company assessment

Direct peers

  • argenx: Commercial-stage autoimmune biotech with efgartigimod (VYVGART), an FcRn antagonist approved for generalized myasthenia gravis — the same lead indication as Vor's UPSTREAM MG Phase 3 program. Directly comparable business model (clinical-to-commercial autoimmune biotech) and target patient population.
  • RemeGen: Chinese biotech that developed telitacicept and is Vor Bio's licensing partner. Holds Chinese commercial rights and manufactures the drug; directly comparable asset (telitacicept itself) and overlapping autoimmune disease focus.

Broad incumbents

  • MorphoSys: Specialty immunology biotech commercializing Monjuvi (tafasitamab) in lymphoma and pipeline assets in autoimmune disease — recently acquired by Novartis. Comparable as an autoimmune/hematology-focused biotech; Vor Bio's CEO Jean-Paul Kress was previously MorphoSys CEO.
  • Sarepta Therapeutics: Commercial-stage biotech with multiple rare disease product launches. Vor Bio's CCO Dallan Murray was previously EVP/CCO at Sarepta; comparable as a rare/specialty disease launch and commercialization platform.
  • Bristol Myers Squibb: Major pharma with extensive autoimmune franchise including Zeposia (SjD/MS), deucravacitinib, and several lupus/RA assets. Competes with Vor Bio's telitacicept pipeline across multiple overlapping indications including SLE and SjD.
  • AbbVie: Major autoimmune franchise with Humira, Rinvoq, and Skyrizi across RA, lupus, and other indications. Vor Bio's CMAO Navid Khan previously led immunology translational science at AbbVie; broad competitive overlap in autoimmune disease.
  • AstraZeneca: Major pharma with autoimmune pipeline including anifrolumab (SLE) and several immunology assets. Competes across multiple of Vor Bio's target indications including lupus, RA, and rare autoimmune diseases.
  • Sanofi: Major pharma with autoimmune franchise including Dupixent and multiple B-cell targeting programs. Vor Bio CEO Jean-Paul Kress serves on Sanofi's board. Competes broadly in immunology and rare autoimmune disease.

Emerging players

  • UCB: Specialty immunology company with rozanolixizumab (Rystiggo) approved for generalized myasthenia gravis — directly competing with Vor's UPSTREAM MG program. Comparable focus on Fc receptor and B-cell pathway modulators in autoimmune neurology.

Others

  • Vertex Pharmaceuticals: Major biotech with growing autoimmune/inflammation franchise. Vor Bio's CCO Dallan Murray previously led Vertex's INCIVEK launch — the fastest biotech launch to $1B at the time. Comparable as a high-growth specialty biotech with strong commercial execution.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Vor Biopharma social profiles

Digital presence

Vor Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vor Biopharma leadership team

Management profile

Number of profiles

Profiles7 records

Vor Biopharma funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vor Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vor Biopharma

What does Vor Biopharma do?

Vor Biopharma is a clinical-stage biotechnology company developing telitacicept, a first-in-class TACI-Fc fusion protein that simultaneously inhibits BAFF and APRIL signaling pathways to treat autoimmune diseases. The company holds ex-Greater China rights licensed from RemeGen and is advancing global Phase 3 trials in generalized myasthenia gravis (UPSTREAM MG) and primary Sjögren's disease (UPSTREAM SjD), while the drug is already commercially approved in China for SLE, RA, and MG.

Is Vor Biopharma a public or private company?

Vor Biopharma is a public company. It is classified as public and is currently operating.

When was Vor Biopharma founded?

Vor Biopharma was founded in 2017. It employs 101 to 250 people.

Where is Vor Biopharma based?

Vor Biopharma is headquartered in Cambridge, United States, in the North America region.

How does Vor Biopharma make money?

Three revenue lines are on record. Telitacicept (ex-Greater China) is the primary driver. The others are remeGen licensing and warrant stake and tens of thousands of patients treated commercially in China.

Who are Vor Biopharma's main competitors?

Direct peers on record are argenx and RemeGen. Broad incumbents are MorphoSys, Sarepta Therapeutics, Bristol Myers Squibb, AbbVie, AstraZeneca and Sanofi. UCB is listed as an emerging player. Vertex Pharmaceuticals is listed as an others.

Does Vor Biopharma have an API?

No public API is recorded for Vor Biopharma.

What industry is Vor Biopharma in?

Vor Biopharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewVor Bio, RemeGen expand collaboration to add autoimmune disease therapyVor Bio amended its agreement with RemeGen to add dual BAFF/APRIL inhibitor RC298, paying up to $356M. The deal includes $56M upfront and up to $300M in milestones, with an exclusive license outside Greater China. RC298 targets an IND in China in H1 2027.Business & FinancialVor Bio Expands Strategic Partnership With Remegen, Adding Next Generation, Long-Acting RC298 To BAFF/APRIL FranchiseVor Bio amended its agreement with RemeGen to add RC298, a long-acting dual BAFF/APRIL inhibitor, to its exclusive license outside Greater China. The deal includes $56 million in upfront consideration and up to $300 million in development milestones. RC298 is in IND-enabling development with an initial filing anticipated in China in the first half of 2027.Stock TitanVor Bio adds RC298 to RemeGen license for ~$56M upfrontVor Bio amended its agreement with RemeGen to add RC298, a long-acting dual BAFF/APRIL inhibitor, to its exclusive license outside Greater China. The deal includes approximately $56 million in upfront consideration and up to $300 million in development milestones. RC298 is in IND-enabling development, with an initial regulatory filing anticipated in the first half of 2027 in China.YahooVor Bio To Participate in 2026 Jefferies Global Healthcare ConferenceVor Bio management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, from 10:30am to 10:55am GMT. The company, focused on telitacicept for autoimmune diseases, will present its Phase 3 clinical development progress.Simply Wall StVor Biopharma (VOR) Cut Quarterly Losses, Is The Stock Still Below Fair Value?Vor Biopharma reported Q3 2026 losses and loss per share sharply lower than a year earlier, alongside a new $150 million at-the-market equity program. The stock closed at $19.88, with a fair value estimate of $39, implying undervaluation. Phase 3 trial enrollment completion is expected in H1 2027.YahooVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Vor Bio's Compensation Committee granted stock options and RSUs to two newly hired employees on November 1, 2026, as inducements under Nasdaq Listing Rule 5635(c)(4). The options cover 24,650 shares at $19.68, and RSUs cover 5,300 shares, both vesting over four years.American Banking and Market NewsVor Biopharma (NASDAQ:VOR) Rating Lowered to “Sell” at Wall Street ZenWall Street Zen downgraded Vor Biopharma to a 'sell' rating, while other analysts have mixed ratings. The stock opened at $19.68, and the company reported a loss of $1.45 per share, missing estimates. The consensus rating is 'Moderate Buy' with a price target of $38.00.MarketBeatVor Biopharma (NASDAQ:VOR) Downgraded by Wall Street Zen to "Sell"Wall Street Zen downgraded Vor Biopharma to a Sell rating, while other analysts have mixed ratings. The company reported Q2 EPS of -$1.45, missing the -$0.81 consensus by -$0.64. Analysts expect a fiscal-year EPS of -$2.56.The future of tradingVor Biopharma Enters Sales Agreement With William Blair And RBC Capital Markets On Oct 30, 2026Vor Biopharma entered a sales agreement with William Blair and RBC Capital Markets on Oct 30, 2026. The company may offer common stock with an aggregate offering price up to $150 million.TradingViewVor Biopharma 3Q 2026: Net loss $86.7M, EPS $(1.45) — 10-Q SummaryVor Biopharma reported a net loss of $86.7 million in Q3 2026, down from $812.7 million a year earlier, with diluted loss per share of $1.45 versus $121.63. The company had no revenue in either quarter. It expects R&D costs to rise as clinical programs progress and does not anticipate product-sales revenue in the near term.